Data Year:

For its 2024 fiscal year, Merck & Co., Inc., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Robert M. Davis
Chairman, Chief Executive Officer and President
Total Compensation $22,674,187 View details Pay Rank By Title In Biotechnology industry #16 View more
Dean Li M.D., Ph.D.
Executive Vice President and President, Merck Research Laboratories
Total Compensation $9,685,860 View details Pay Rank By Title In Biotechnology industry #10 View more
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Total Compensation $7,507,778 View details Pay Rank By Title In Biotechnology industry #21 View more
Richard R. DeLuca Jr.
Executive Vice President and President, Merck Animal Health
Total Compensation $8,829,773 View details Pay Rank By Title In Biotechnology industry #12 View more
Betty Larson
Executive Vice President and Chief Human Resources Officer
Total Compensation $11,225,691 View details Pay Rank By Title In Biotechnology industry #4 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at Merck & Co., Inc. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Merck & Co., Inc. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Merck & Co., Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Robert M. Davis
Chairman, Chief Executive Officer and President
Total Cash $4,385,524 Equity $17,727,551 Other $561,112 $22,674,187
Dean Li M.D., Ph.D.
Executive Vice President and President, Merck Research Laboratories
Total Cash $3,110,917 Equity $6,404,760 Other $170,183 $9,685,860
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Total Cash $2,499,844 Equity $4,860,724 Other $147,210 $7,507,778
Richard R. DeLuca Jr.
Executive Vice President and President, Merck Animal Health
Total Cash $2,055,427 Equity $6,659,835 Other $114,511 $8,829,773
Betty Larson
Executive Vice President and Chief Human Resources Officer
Total Cash $2,014,642 Equity $8,930,726 Other $280,323 $11,225,691
For its 2024 fiscal year, Merck & Co., Inc., listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Robert M. Davis CEO Pay $23,186,064 Median Employee Pay $106,091 CEO Pay Ratio 219:1
For its 2024 fiscal year, Merck & Co., Inc., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Douglas M. Baker, Jr. Total Cash $350,000
Inge G. Thulin Total Cash $340,000
Kathy J. Warden Total Cash $350,000
Mary Ellen Coe Total Cash $340,000
Pamela J. Craig Total Cash $403,750
Patricia F. Russo Total Cash $363,750
Paul B. Rothman, M.D. Total Cash $413,750
Peter C. Wendell Total Cash $78,791
Risa J. Lavizzo-Mourey, M.D. Total Cash $361,000
Stephen L. Mayo, Ph.D. Total Cash $350,000
Thomas H. Glocer Total Cash $436,250
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.